Subsidised Access to Columvi® Now Available for Eligible Patients with Relapsed or Refractory DLBCL in Singapore
Columvi (glofitamab) will be added to the Cancer Drug List (CDL) and Medication Assistance Fund (MAF) on 1 September 2026 for eligible patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for autologous...
MCO (MyComplianceOffice) Rises to Number 17 on Chartis Research's Financial Crime and Compliance50 2026
NEW YORK, March 10, 2026 /PRNewswire/ -- MCO (MyComplianceOffice), a leading provider of compliance management software for financial services firms, has been named to Chartis Research's Financial Crime and Compliance50 (FCC50) for the second...
Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List
SAN FRANCISCO and SUZHOU, China, Dec. 7, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of...
